News

BioScience Co., Ltd. continues to expand its global footprint with the establishment of BioScience USA Inc., its U.S. subsidiary dedicated to supporting customers across North America. The new entity is designed to enhance local sales, logistics, and technical service capabilities, providing more efficient and responsive support to regional clients.With a dedicated local team, BioScience USA Inc. enables faster communication, improved service response times, and more reliable after-sales support. The company works closely with research institutions, universities, and industry partners to deliver laboratory instruments, consumables, and customized solutions tailored to diverse application needs.The establishment of BioScience USA Inc. reflects BioScience’s long-term commitment to the North American market. By strengthening its local presence, the company aims to provide consistent, high-quality service and build closer partnerships with customers throughout the region.

Subheading: A technology-driven service provider combines gold-standard accuracy with long-read capability to tackle challenging sequences.For Immediate Release – Researchers grappling with complex genomic regions, structural variations, or the need for full plasmid verification now have a powerful ally. Biosune, a sequencing service specialist, leverages a dual-platform strategy integrating Sanger sequencing and Nanopore long-read technology to deliver end-to-end solutions from routine validation to de novo analysis of challenging templates.Precision Meets Length: The Two-Pillar Technology StrategyBiosune’s core strength lies in its complementary technology portfolio. Its Sanger sequencing service remains the industry benchmark for applications requiring utmost base-by-base accuracy (>99.99%), such as PCR product verification, plasmid construct confirmation, and SNP analysis. In parallel, its Nanopore sequencing service offers true single-molecule, real-time long-read capability. This amplification-free technology sequences native DNA/RNA, generating reads spanning tens of kilobases, which is ideal for resolving structural variants, sequencing full-length plasmids, and deciphering high-GC or highly repetitive regions that are problematic for short-read technologies.Guidance for the Right Tool: Matching Technology to ApplicationTo help researchers select the optimal approach, Biosune provides clear guidance based on extensive project experience. For projects involving full plasmid sequencing, low-frequency variant detection, or complex amplicons, Nanopore sequencing offers a cost-effective and comprehensive solution. For routine clone screening or validation of short constructs, Sanger sequencing provides speed and precision. The company also publishes detailed sample submission guidelines (e.g., PCR products ≥20 ng/μL, avoidance of UV exposure) to ensure optimal data quality from the start.Operational Excellence: Scale, Speed, and Quality AssuranceBiosune’s reliability is built on a robust operational backbone. The company operates multiple laboratories across China, supported by nearly 30 high-capacity sequencers, enabling a daily throughput of up to 30,000 reactions. This infrastructure allows for rapid turnaround, with the fastest delivery in as little as 10 hours for urgent projects. Quality is ingrained at every level: Biosune is certified under both ISO 9001 (Quality Management) and ISO 13485 (Medical Devices) standards. Its customer-centric support system includes free re-runs for anomalous Sanger results and multi-channel technical assistance.About BiosuneBiosune specializes in providing high-precision, reliable DNA sequencing services to the global life science research community. With a founding team possessing over 30 years of expertise and a commitment to technological innovation, Biosune has served more than 30,000 clients, empowering research from basic science to applied diagnostics.

Marking a significant milestone in the rapidly evolving field of genomics, Labwave proudly announces the global launch of the WaveQPro Sequencing System (Model: WS-Q1000). As a flagship product of fourth-generation sequencing technology, it officially marks the industry's entry into the SNS (Single-molecule Nanopore Sequencing) era.Breakthrough Technology Redefining the Sequencing ExperienceThe WS-Q1000 is based on the innovative principle of single-molecule nanopore sequencing. It utilizes a coordinated system of nanopore proteins, DNA polymerases, DNA templates, and free nucleotides with signal-bearing linkers. As the polymerase replicates the DNA template with high fidelity, the system captures the characteristic electrical signals generated when nucleotide linkers transiently block the nanopore. Coupled with specially trained AI algorithms for signal analysis, the system achieves Q30+ (accuracy >99.9%) single-molecule sequencing quality.Key Performance Highlights:l Q30+ Data Quality: Single-molecule accuracy exceeding 99.9%, meeting the demands of high-precision research and clinical applications.l Ultra-Fast Turnaround: Run times from just 10 minutes to 6 hours, dramatically shortening waiting periods.l Solid-State Flow Cell: Offers enhanced stability and can be reused for up to 10 runs.l Ultra-High Throughput: Supports up to 1.25 million sequencing channels per run, generating over 50 million reads per flow cell in short-fragment mode.l Wide Read Length Range: Accommodates fragments from 20 bp to 15 kb, covering diverse application needs.l User-Friendly Operation: Features a highly automated system design for truly "plug-and-play" simplicity.Labwave is committed to advancing the commercialization and accessibility of fourth-generation sequencing. The WaveQPro platform, with its high accuracy, throughput, and low operational barrier, aims to empower diverse fields including life science research, precision medicine, pathogenic microbe detection, and agricultural breeding. The launch of the WS-Q1000 is not merely a technological upgrade but a pivotal milestone for the sequencing industry.

Subheading: The synthesis provider combines deep technical mastery, scalable production, and rigorous QC to serve advanced research and diagnostic applications.For Immediate Release – The demand for high-quality, complex synthetic nucleic acids is surging in fields like molecular diagnostics, therapeutic development, and advanced research. Meeting this demand requires not just synthesis capability, but deep expertise in chemistry, modifications, and scale. BioPohe, with over 30 years of focused experience, has established itself as a trusted partner for custom oligonucleotide and gene synthesis, supporting clients worldwide.A Comprehensive Portfolio: From Nano-Scale Modifications to Full GenesBioPohe’s service breadth addresses a wide spectrum of needs. Its oligonucleotide synthesis capabilities encompass DNA Oligos (10-100 bases), single-stranded RNA, siRNA, miRNA, and ASOs. A key differentiator is its extensive library of over 100 chemical modifications, including fluorescent dyes, quenchers, affinity tags (e.g., biotin), backbone modifications (e.g., phosphorothioate), and nucleotides with altered sugar chemistry (2’-OMe, 2’-F). For larger constructs, BioPohe offers a complete gene synthesis workflow, from sequence design and codon optimization to synthesis, cloning, and 100% validation by Sanger sequencing, with support for custom vectors.The Foundation of Trust: Stringent, Multi-Layered Quality ControlProduct consistency and purity are paramount. BioPohe manufactures in a 500 m² ISO Class 8 (Class 100,000) cleanroom utilizing state-of-the-art automated synthesis platforms. Quality is verified through orthogonal methods: Mass Spectrometry (MS) for sequence identity, HPLC for purity assessment, and PAGE for length verification. This rigorous process is governed by a certified ISO 9001 and ISO 13485 quality management system, ensuring full traceability from raw materials to final shipment.Scalable for Every Stage: From R&D Screens to Industrial SupplyBioPohe is equipped to support projects at any scale. For early-stage research, it offers small-scale synthesis (from 2 OD) with options for next-day delivery. When projects transition to development and production, the company’s platform can seamlessly scale to single-batch synthesis runs as large as 25,000 OD with minimal batch-to-batch variation, providing a reliable supply chain for diagnostic and therapeutic applications.About BioPoheA subsidiary of Shanghai BioScience Co., Ltd., BioPohe is dedicated to the synthesis of high-purity nucleic acids. Leveraging decades of expertise in nucleic acid chemistry and a modern, certified production facility, BioPohe delivers custom oligonucleotides and genes that meet the exacting standards of global research, diagnostic, and pharmaceutical partners.

As research in cell therapy, organoids, stem cells, and tumor microenvironment simulation advances, the demand for truly stable, precise, compact, and independent personal cell culture devices has become urgent. Addressing this need, the WavePod R&D team has successfully developed the WavePod Mini Tri-Gas Incubator (Model: WP-0012) after two years of dedicated effort. The product is completing its final development phase and preparing for market launch. Breakthrough 1: High-Precision Multi-Gas Coordinated Control in a Micro-ChamberAchieving rapid response and stable control of four parameters—O₂, CO₂, temperature, and humidity—within a compact 12-liter volume. The team developed proprietary multi-variable coordinated control algorithms coupled with high-sensitivity sensors, delivering:l CO₂ control accuracy: ±0.1%l O₂ control range: 0.1%–21% (95% optional), accuracy: ±0.25% Vol.l Temperature stability: ≤±0.1°C, uniformity: ≤±0.3°CThis precision sets a new international benchmark among comparable compact tri-gas incubators.Breakthrough 2: ≤10-Minute Rapid Recovery Post-Door OpeningDoor openings for sampling disturb the culture environment, impacting experimental repeatability. Through dynamic compensation strategies and optimized airflow design, WavePod Mini achieves recovery of temperature, CO₂, and O₂ to setpoints within ≤10 minutes after a 30-second door opening.Breakthrough 3: Five-Color Light Feedback SystemMoving beyond reliance on screens or apps for status checks, the team innovatively integrated a full-ring LED light strip with control logic. Five distinct colors provide instant, at-a-glance status from a distance: Green (Running), Red (Alarm), Blue (Door Open), Purple (Sterilization), White (Standby). This represents a significant leap in intuitive human-machine interaction.Breakthrough 4: High Airtightness & Low-Interference DesignFeaturing a seamless, rounded 316L mirror-finish stainless steel interior for easy cleaning; an integrated heated door with hydraulic damping and magnetic seal for quiet, self-sealing closure; and independent gas inlets with ≤0.3μm intake filtration to prevent cross-contamination. These features fulfill the core design philosophy: "One Chamber, One User. No Interference."Message from the R&D Team:"We weren't just building a smaller incubator; we were creating a truly personal device that matches the stability of large systems. Every precision improvement and reduction in recovery time is the result of dozens of iterations and learning from failures."WavePod Mini has completed engineering verification and performance testing, entering the user trial phase, with official orders expected to open in Q3 2026.